Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ACTRN12626000470392) titled 'Ultra-hyPofractionated stereotactic Radiation therapy for de nOvo Metastatic ProsTate cancer (PROMPT)' on April 16.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Alfred Hospital
Condition:
De novo metastatic prostate cancer
De novo metastatic prostate cancer
Cancer - Prostate
Intervention:
Patients will receive stereotactic ablative body radiotherapy (SABR) to the prostate delivered in five fractions, one fraction per week. Each SABR session will take approximately 30 minutes, This study will aim to deliver 5-fraction prostate SABR 35 GY ...